The mega-merger deal between Canadian cannabis companies Aphria and Tilray (NASDAQ:TLRY) was the highlight of the marijuana industry this year. The deal closed on May 3 and the new Tilray was formed, and in the process, became the worlds largest cannabis company by revenue.
The legacy Aphria has always been a strong contender in the cannabis space because of its smart growth strategies. Legacy Tilray, on the other hand, was a rather small company, which had a market cap of $1.1 billion before the merger was announced, but now holds a market cap of $7.7 billion.
This brought the newly combined company closer to the two leaders in the cannabis space: U.S. cannabis company Curaleaf Holdings, with a market cap of $9.5 billion, and Ontario, Canada-based Canopy Growth, with a market cap of $9.0 billion.
Since this was a reverse merger, the legacy Aphrias management holds the decision-making powers. In fact, Aphrias shareholders now own 62% of the new company, with Irwin Simon (Aphrias CEO and chairman) leading the combined entity. Here are all the ways Tilray can benefit from this merger, and why this business is a smart buy for the long term.
Image source: Getty Images.
Whats in this merger deal for Tilray?
Mergers and acquisitions are not uncommon in the marijuana industry. Before this merger, Aphria acquired American craft beer maker SweetWater Brewing in November 2020 to make an entry into the U.S. cannabis beverage market. Beverages are part of cannabis derivatives (vapes, edibles, concentrates, and more), additional recreational products that Canada legalized in October 2019. Tilray had already made an entry into this category in October with a new line of cannabis-infused edibles through its wholly owned subsidiary High Park Holdings. By pooling its resources and capital, the combined company can launch even more derivatives, competing with peers like Canopy that are rapidly expanding in this segment
In its recent fourth-quarter fiscal 2020 results, the legacy Tilray recorded a 20.5% year-over-year jump in revenue to $57 million. For the full year, the company reported a 26% increase in revenue to $210 million from 2019. Tilray also saw a positive adjusted EBITDA (earnings before income, tax, depreciation, and amortization) of $2.2 million, compared to a loss of $35.3 million in the year-ago period. This was Tilrays first quarter of positive EBITDA before merging with Aphria -- and it is a good start.
Aphria has been generating positive adjusted EBITDA over the past seven quarters. Now, Aphrias strong balance sheet and its management driving the bus can make the new Tilray a profitable cannabis company. (EBITDA measures a companys operational performance, whereas true profitability is the total earnings after all deductions are made.) By merging with Aphria, Tilray has equipped itself to both expand and grow.
A steady hand on the wheel
A bigger company has some benefits -- access to a lot of resources, manpower, and capital. But bigger is not always better. A bigger company can also be difficult to manage. It could face complications with cost synergies, hidden inefficiencies, merger costs, and personnel. Thats why Irwins leadership is so important -- we can expect the company to smoothly handle any challenges.
As CEO, Irwin successfully founded and led consumer goods company Hain Celestial Group to success before doing the same for Aphria. Aphria survived and thrived amid a global crisis because of Simon and his leadership teams smart growth strategies of focusing on their core operations and strengthening their brands and balance sheet, rather than spending cash haphazardly on acquisitions. It appears Simon plans to follow the same strategy for new Tilray -- building its existing brands and focusing on its roots in Canada.
On June 8, Tilray launched a new medical cannabis brand, Symbios, and a high-potency medical cannabis topical under the Aphria brand for the Canadian market.
A smart buy for the long term
The European cannabis market could grow at a compound annual growth rate of 29.6% to be worth $37 billion by 2027. This could be a lucrative opportunity for Tilray. Simon expects to use Tilrays Portugal facility to help in expanding into the European market. The company holds a cultivation license from the government of Portugal to produce medical marijuana products and export them throughout the continent.
Aphria already has a strong market presence in the medical cannabis business not only in Canada and Europe, but also in Africa, South America, and Oceania. It generates close to 97% of its distribution revenue from its Germany-based subsidiary, CC Pharma.
With prospects of federal legalization in the U.S. also strengthening, the new Tilray could be a strong contender in the U.S. cannabis market five years down the line. In the meantime, the European, international, and Canadian markets can be its revenue growth driver for now. We will know more about the new Tilrays performance and its long-term growth strategies when it reports its next quarterly results. Management expects the mergers operational efficiencies to generate $81 million in annual pre-tax cost-saving synergies within 18 months.
If you have faith in the growth of the marijuana industry, Tilray is a smart buy for the long term. Two strong companies with an expanded international presence, strong balance sheet, growing revenues moving closer to profitability, and a good leadership team are all set to become a cannabis powerhouse. That said, do not expect any short-term gains, as a merger integration takes time. So if you can bear the short-term risks to enjoy fruitful gains in the future, this cannabis stock is for you.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.Sushree Mohanty has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.>
Motley Fool Returns
Stock Advisor S&P 500
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 08/31/2021.
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return
Find us at the office
Humble- Micallef street no. 52, 81559 Jakarta, Indonesia
Give us a ring
+27 450 860 545
Mon - Fri, 9:00-18:00